Targeting the eicosanoid pathway in non-small-cell lung cancer

Leora Horn, Michael Backlund, David H. Johnson

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Multiple lines of evidence suggest that cyclooxygenase-2 (COX-2) upregulation is an early event in the development of non-small-cell lung cancer. Preclinical data indicate tumors with upregulation of COX-2 synthesize high levels of prostaglandin E2 (PGE2), which in turn are associated with increased production of proangiogenic factors and enhanced metastatic potential. These findings indicate that an increase in COX-2 expression may play a significant role in the development and growth of lung cancers and possibly with the acquisition of an invasive and metastatic phenotype. Consequently, inhibitors of COX-2 are being studied for their chemopreventative and therapeutic effects in individuals at high risk for lung cancer and patients with established cancers.

Original languageEnglish (US)
Pages (from-to)675-688
Number of pages14
JournalExpert Opinion on Therapeutic Targets
Volume13
Issue number6
DOIs
StatePublished - Jun 2009

Fingerprint

Eicosanoids
Cyclooxygenase 2
Non-Small Cell Lung Carcinoma
Cells
Lung Neoplasms
Up-Regulation
Cyclooxygenase 2 Inhibitors
Therapeutic Uses
Growth and Development
Dinoprostone
Tumors
Neoplasms
Phenotype

Keywords

  • Cyclooxygenase-2
  • Eicosanoids
  • Non-small-cell lung cancer
  • Prostaglandin E

ASJC Scopus subject areas

  • Drug Discovery
  • Pharmacology
  • Clinical Biochemistry
  • Molecular Medicine

Cite this

Targeting the eicosanoid pathway in non-small-cell lung cancer. / Horn, Leora; Backlund, Michael; Johnson, David H.

In: Expert Opinion on Therapeutic Targets, Vol. 13, No. 6, 06.2009, p. 675-688.

Research output: Contribution to journalArticle

@article{7baf0d07a8ff4547845ea35e5c18d9cf,
title = "Targeting the eicosanoid pathway in non-small-cell lung cancer",
abstract = "Multiple lines of evidence suggest that cyclooxygenase-2 (COX-2) upregulation is an early event in the development of non-small-cell lung cancer. Preclinical data indicate tumors with upregulation of COX-2 synthesize high levels of prostaglandin E2 (PGE2), which in turn are associated with increased production of proangiogenic factors and enhanced metastatic potential. These findings indicate that an increase in COX-2 expression may play a significant role in the development and growth of lung cancers and possibly with the acquisition of an invasive and metastatic phenotype. Consequently, inhibitors of COX-2 are being studied for their chemopreventative and therapeutic effects in individuals at high risk for lung cancer and patients with established cancers.",
keywords = "Cyclooxygenase-2, Eicosanoids, Non-small-cell lung cancer, Prostaglandin E",
author = "Leora Horn and Michael Backlund and Johnson, {David H.}",
year = "2009",
month = "6",
doi = "10.1517/14728220902915567",
language = "English (US)",
volume = "13",
pages = "675--688",
journal = "Expert Opinion on Therapeutic Targets",
issn = "1472-8222",
publisher = "Informa Healthcare",
number = "6",

}

TY - JOUR

T1 - Targeting the eicosanoid pathway in non-small-cell lung cancer

AU - Horn, Leora

AU - Backlund, Michael

AU - Johnson, David H.

PY - 2009/6

Y1 - 2009/6

N2 - Multiple lines of evidence suggest that cyclooxygenase-2 (COX-2) upregulation is an early event in the development of non-small-cell lung cancer. Preclinical data indicate tumors with upregulation of COX-2 synthesize high levels of prostaglandin E2 (PGE2), which in turn are associated with increased production of proangiogenic factors and enhanced metastatic potential. These findings indicate that an increase in COX-2 expression may play a significant role in the development and growth of lung cancers and possibly with the acquisition of an invasive and metastatic phenotype. Consequently, inhibitors of COX-2 are being studied for their chemopreventative and therapeutic effects in individuals at high risk for lung cancer and patients with established cancers.

AB - Multiple lines of evidence suggest that cyclooxygenase-2 (COX-2) upregulation is an early event in the development of non-small-cell lung cancer. Preclinical data indicate tumors with upregulation of COX-2 synthesize high levels of prostaglandin E2 (PGE2), which in turn are associated with increased production of proangiogenic factors and enhanced metastatic potential. These findings indicate that an increase in COX-2 expression may play a significant role in the development and growth of lung cancers and possibly with the acquisition of an invasive and metastatic phenotype. Consequently, inhibitors of COX-2 are being studied for their chemopreventative and therapeutic effects in individuals at high risk for lung cancer and patients with established cancers.

KW - Cyclooxygenase-2

KW - Eicosanoids

KW - Non-small-cell lung cancer

KW - Prostaglandin E

UR - http://www.scopus.com/inward/record.url?scp=67649607484&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67649607484&partnerID=8YFLogxK

U2 - 10.1517/14728220902915567

DO - 10.1517/14728220902915567

M3 - Article

VL - 13

SP - 675

EP - 688

JO - Expert Opinion on Therapeutic Targets

JF - Expert Opinion on Therapeutic Targets

SN - 1472-8222

IS - 6

ER -